IDV vehicle
36E79724D0024
NEW AWARD FOR UBLITUXIMAB-XIIY 150MG/6ML INJECTION (ANTI-CD20 ANTIBODIES WITH TG THERAPEUTICS. PERIOD OF PERFORMANCE JUNE 17, 2024 - JUNE 16, 2025 WITH FOUR ONE-YEAR OPTIONS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Veterans Affairs |
| Office | NAC PHARMACEUTICALS (36E797) |
| NAICS | 325412 — Pharmaceutical Preparation Manufacturing |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $0 |
| Current contract value | Not reported |
| Potential contract value / ceiling | $186.8M |
| Start date | Jun 17, 2024 |
| Current end date | Not available |
| Potential end date | Not available |
| Latest award activity | Sep 2, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 8 of 8 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 2, 2026 | P00007 | $0 | THIS MODIFICATION INCORPORATES SECTION 5 OF EO 14398, CLAUSE 52.222-90, ADDRESSING DEI DISCRIMINATION |
| Apr 28, 2026 | P00006 | $0 | THIS MODIFICATION IS ISSUED TO EXERCISE OPTION YEAR TWO FOR ANTI-CD20 ANTIBODIES WITH TG THERAPEUTICS. |
| Nov 25, 2025 | P00005 | $0 | THIS MODIFICATION INCORPORATES 2026 PUBLIC LAW PRICING UPDATES INTO THE CONTRACT. THERE ARE NO CHANGES TO THE AWARDED CONTRACT PRICING. |
| May 15, 2025 | P00004 | $0 | THIS MODIFICATION IS ISSUED TO EXERCISE OPTION YEAR ONE FOR ANTI-CD20 ANTIBODIES WITH TG THERAPEUTICS. |
| Nov 21, 2024 | P00003 | $0 | THIS MODIFICATION INCORPORATES 2025 PUBLIC LAW PRICING UPDATES INTO THE CONTRACT. THERE ARE NO CHANGES TO THE AWARDED CONTRACT PRICING. |
| Sep 24, 2024 | P00002 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE A CHANGE OF ADDRESS INTO VA NATIONAL CONTRACT 36E79724D0024. |
| Jul 23, 2024 | P00001 | $0 | THIS MODIFICATION IS ISSUED TO UPDATE THE TERMS OF THE CRF PAYMENT REMITTAL AND SUBMISSION OF QUARTERLY SALES REPORTS. |
| Apr 17, 2024 | 0 | $0 | NEW AWARD FOR UBLITUXIMAB-XIIY 150MG/6ML INJECTION (ANTI-CD20 ANTIBODIES WITH TG THERAPEUTICS. PERIOD OF PERFORMANCE JUNE 17, 2024 - JUNE 16, 2025 WITH FOUR ONE-YEAR OPTIONS. |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Youlanda Duggar | Contract Specialist | youlanda.duggar@va.gov | Source | Feb 5, 2024 |
| Youlanda Duggar | Contract Specialist | youlanda.duggar@va.gov | Source | Jan 29, 2024 |
| Youlanda Duggar | Contract Specialist | youlanda.duggar@va.gov | Source | Jan 26, 2024 |
| Youlanda Duggar | Contract Specialist | youlanda.duggar@va.gov | Source | Jan 25, 2024 |
| Contract Specialist | Youlanda Duggar | Youlanda.Duggar@va.gov 708-786-4943 | Source | Jan 19, 2024 |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.